Artrya's Salix® Platform Launches at Northeast Georgia Health System, Initiating Revenue with Second U.S. Customer

Salix® Platform Achieves Clinical Deployment at Prominent Georgia Health System

On 23 July 2026, Artrya Limited announced the successful clinical launch of its AI-powered Salix® platform at Northeast Georgia Health System, a significant commercial milestone for the Perth-based medtech company. The platform is actively used at the first of NGHS's five hospitals and outpatient facilities, with plans to expand across all sites in the near future. This deployment marks Artrya's second U.S. customer to implement Salix® clinically after comprehensive integration and clinical team training.

The Georgia Heart Institute, one of Georgia’s largest cardiology programs and part of NGHS, now incorporates Salix® outputs into routine diagnostic workflows. Serving over 100,000 patients annually, the institute provides substantial exposure for the platform. Clinicians utilize the technology to assist diagnosis in patients with suspected or confirmed coronary artery disease, with strong clinical engagement supporting anticipated wider adoption across the health system.

Revenue Model Based on Subscriptions and Fee-Per-Scan Licensing

At NGHS, the Salix® platform generates revenue through multiple streams aligned with Artrya’s technology suite components. Monthly subscription fees are earned from Salix® Coronary Anatomy, licensed as a Software-as-a-Service (SaaS) to healthcare providers, offering recurring revenue visibility as adoption expands across NGHS facilities.

Additionally, Artrya receives fee-per-scan payments from the Salix® Coronary Plaque module as clinicians analyze coronary CT angiography (CCTA) scans for patients with suspected or confirmed coronary artery disease. The Salix® Coronary Flow module, pending FDA clearance, will be activated for clinical use upon approval and will also generate fee-per-scan revenue. This tiered revenue approach captures value across various clinical applications as patients progress through diagnostic workflows.

Artrya's AI Platform for Coronary Artery Disease Detection

Headquartered at 1257 Hay Street, West Perth, Western Australia, Artrya Limited develops AI-powered solutions targeting improved detection and management of coronary artery disease, a leading global cause of morbidity and mortality. Its proprietary Salix® software analyzes coronary CT scans to identify key heart disease biomarkers, aiding clinicians in delivering more accurate and efficient diagnoses.

The technology offers real-time, point-of-care assessment integrated into existing clinical workflows. By automating CT imaging analysis and providing structured outputs on coronary anatomy and plaque features, Salix® enhances diagnostic accuracy and efficiency in cardiovascular care. Artrya is advancing regulatory and commercial initiatives internationally, with multiple U.S. foundation partners progressing toward commercial deployment.

Northeast Georgia Health System Marks Second U.S. Customer Deployment

The Salix® go-live at Northeast Georgia Health System validates Artrya’s platform within a major U.S. health system. NGHS operates five hospitals and outpatient centers across Georgia, offering significant deployment scale. Their decision to implement Salix® across the network reflects confidence in the platform’s clinical and commercial value.

This deployment is Artrya’s second U.S. customer clinical use milestone. John Konstantopoulos, Co-Founder and CEO of Artrya, stated that "the team has worked incredibly hard to integrate Salix® and train the NGHS clinical team over recent months," expressing enthusiasm about Georgia Heart Institute cardiologists using Salix® on real patients and gaining confidence. Management also anticipates Cone Health, another U.S. foundation partner, going live soon, indicating momentum in U.S. market penetration.

Phased Multi-Site Rollout Across NGHS Network

Artrya is implementing a phased rollout at NGHS, starting with one hospital and outpatient facility before expanding to the remaining four sites. This approach facilitates effective training, integration, and clinical workflow optimization throughout the network. Full support for all five NGHS hospitals is planned shortly, establishing a clear expansion timeline.

This phased strategy benefits both Artrya and NGHS by managing operational complexity and ensuring strong clinical adoption. Beginning with the Georgia Heart Institute allows Artrya to refine implementation based on early feedback and demonstrate value to other sites. Once fully deployed, the subscription and fee-per-scan revenue models will apply system-wide, presenting significant growth potential.

Integration into Cardiology Workflow and Program Support

Salix® integration within the Georgia Heart Institute’s diagnostic workflow highlights its practical clinical utility. Serving over 100,000 patients annually, the institute’s cardiologists now routinely use Salix® outputs for patients with suspected or confirmed coronary artery disease. This seamless incorporation into existing diagnostic processes is vital for medical technology adoption.

Strong clinical engagement observed supports anticipated broader adoption across NGHS. Physician confidence in Salix®’s accuracy and usefulness is critical for widespread acceptance. The successful deployment at a large cardiology program positions Artrya to showcase Salix®’s clinical value and volume potential to other U.S. health systems.

U.S. Foundation Partners and Commercialization Progress

Artrya’s update reveals three U.S. foundation partners in its commercialization strategy. Northeast Georgia Health System is the second to achieve commercial status with Salix®. The company is "on track for all three U.S. foundation partners to be commercial soon," indicating the third partner’s deployment and revenue generation are forthcoming.

Transitioning foundation partners from pilot phases to full commercial deployment signals strong market traction and validation. Each successful deployment provides clinical evidence, workflow integration experience, and revenue streams supporting further sales to additional health systems. Management’s confidence in commercializing all three partners reflects positive momentum in Artrya’s U.S. expansion.

FDA Clearance Pending for Salix® Coronary Flow Module

The Salix® platform includes several modules, with Coronary Anatomy and Coronary Plaque now in routine clinical use at NGHS. The Coronary Flow module awaits FDA clearance for clinical deployment. Upon approval, it will be activated and generate additional fee-per-scan revenue through patient assessments.

This phased activation of modules as regulatory approvals occur expands Salix®’s clinical and revenue potential within existing customers. The pending FDA clearance for the Coronary Flow module highlights ongoing innovation to enhance diagnostic capabilities and revenue opportunities. Investors should watch for FDA approval as a near-term catalyst for revenue growth at NGHS and other deployments.

Growing Commercial Momentum and Market Validation for Artrya

Salix®’s deployment at Northeast Georgia Health System and commencement of revenue mark key validation milestones for Artrya’s technology and business model. NGHS’s multi-site implementation underscores confidence from a major U.S. healthcare provider in the clinical utility and commercial value of Salix®.

Revenue generation at the second U.S. customer, alongside management’s expectation that all three foundation partners will commercialize soon, indicates strong U.S. market progress. Converting foundation partners from pilots to commercial deployments, combined with NGHS’s multi-site rollout, positions Artrya for broader health system adoption. Investors will monitor Cone Health’s commercialization timeline and the wider sales pipeline as indicators of scaling beyond foundation partners.